
Personalized translational medicine: Investigating YKL-40 as early biomarker for clinical risk stratification in hepatocellular carcinoma recurrence post-liver transplantation.
YKL-40 shows promise as a biomarker for HCC recurrence post-liver transplantation, enhancing risk stratification. 📊🔍